rxpertusa logo spacer rxpertusa wings
logo spacer spacer spacer
spacer home
about us
assessment tools
sample consult
contact us

red line

spacer spacer news

The latest Mainline newsletters for the General Public are listed here.


For healthcare professionals we have a Mainline newsletter in a Professional version here.

Printer Friendly


Volume 2 October 17, 2005 Number 7

An Exclusive Continuing Education Publication of Acadiana Consultant Pharmacy Service
Author, Publisher, Editor-in Chief, Typesetter & Printer, Charles S. Feucht,PD,FASCP PharmD candidate

Medication News & Update

On October 17, Eli Lilly and the Food and Drug Administration (FDA) notified health care professionals of a revision to the “Precautions” section of the prescribing information for duloxetine (Cymbalta). Postmarketing reports of liver injury (including hepatitis and jaundice) suggest that patients with preexisting liver disease who take duloxetine may have an increased risk for further liver damage. The new labeling extends the precaution against using duloxetine in patients with substantial alcohol use to include those patients with chronic liver disease. It is recommended that duloxetine not be administered to patients with any liver problems. For more information, visit http://www.fda.gov/medwatch/safety/2005/safety05.htm#Cymbalta



Home ] [ About Us  ] [ Assessment Tools  ] [ Sample Consult  ]
Contact Us  ]

Copyright © www.rxpertusa.com. Designed by PcHousekeeping.com
  spacer spacer